sermorelin research: Frequently asked questions

Verify administration timing and technique. Sermorelin must be administered subcutaneously 30–60 minutes before sleep on an empty stomach (no food for 2–3 hours prior). Blood glucose elevation from recent meals blunts GH release through somatostatin upregulation. If administration is correct, non-response suggests pituitary hypofunction or GHRH receptor desensitization from prior exogenous GH use. Order baseline pituitary MRI and consider switching to a ghrelin mimetic like ipamorelin, which works through a different receptor pathway.

Sermorelin stacks synergistically with ipamorelin or GHRP-2 because they work through different receptor pathways. Sermorelin stimulates GHRH receptors, while ghrelin mimetics stimulate GHSR1a receptors. The combined effect produces higher-amplitude GH pulses than either peptide alone. Standard research stack: sermorelin 200–300 mcg + ipamorelin 200 mcg subcutaneously before bed. Do NOT stack sermorelin with CJC-1295 DAC. The prolonged half-life of CJC-1295 flattens pulsatility and increases suppression risk. Investigate products like the Muscle Building Recovery Bundle for research-grade peptide combinations.

Transient insulin resistance during the first 4–8 weeks is expected. GH acutely increases hepatic glucose output, which triggers compensatory insulin secretion. If fasting insulin remains elevated beyond 12 weeks or HbA1c increases, reduce sermorelin dose by 30–40% and reassess. Persistent hyperinsulinemia suggests the patient's metabolic state cannot tolerate increased GH flux. Typically seen in individuals with pre-existing insulin resistance or visceral adiposity above 35% body fat. Prioritize fat loss through caloric deficit before escalating GH protocols.

Document it immediately in the sermorelin research log track document with the exact timeline and temperature range, then flag all doses administered from that batch as potentially compromised. Do not discard the peptide yet. Stability data from the manufacturer may indicate tolerance for brief excursions. Contact the peptide supplier with your documented excursion details (temperature, duration, whether the vial was opened) and request guidance on continued use. If the study timeline allows, run a potency assay on the affected batch before proceeding.

Record the exact ratio used (water volume in ml : peptide mass in mg) in the sermorelin research log track document, calculate the resulting concentration, and note the reason for deviation (e.g., study design requires lower concentration for precise dosing). Non-standard ratios are acceptable as long as they're documented and consistent across all study subjects. The critical error is using different ratios within the same study without tracking which subjects received which concentration. That introduces an uncontrolled variable that invalidates cross-subject comparisons.

Do not extend use of reconstituted sermorelin beyond 28 days refrigerated. Degradation accelerates after this point regardless of appearance. Instead, reconstitute a fresh vial from lyophilised powder and document the batch transition in your sermorelin research log track document. Record the new vial's lot number, reconstitution timestamp, and concentration. If comparing outcomes across the batch transition, include a control group that receives both old and new batches during an overlap period to identify any batch-to-batch variability.

Run secondary structure verification through CD spectroscopy and aggregation analysis through DLS. We've documented cases where sermorelin met purity specifications but showed 30–40% aggregation in solution. The aggregated peptide doesn't engage GHS-R1a receptors effectively, leading to dose-response curves that don't match published literature. If structural analysis confirms degradation, the batch should be replaced even though it technically passed purity thresholds. For research requiring reproducible dose-response relationships, structural integrity matters more than raw purity percentages.

Implement a centralized chain-of-custody database with temperature logger integration at each site. Every freezer holding research peptides should have continuous monitoring with cloud-based alert systems that flag temperature excursions in real time. When transferring aliquots between labs, use validated shipping containers with time-temperature indicators (TTIs) that provide irreversible visual confirmation of thermal exposure. This distributed documentation model allows any researcher in the collaboration to verify storage conditions for every sample used. Critical for multi-site trials where reproducibility depends on material consistency.

Reject the shipment and request documented cold-chain verification. Peptides exposed to ambient temperature (20–25°C) for unknown durations may show normal appearance and pass basic purity checks while having significantly reduced bioactivity. The structural degradation that occurs during temperature excursions isn't always detectable without CD spectroscopy. Which means your experimental results could show high variability or complete lack of effect without understanding why. Reputable suppliers provide temperature data logs as standard practice, and their absence signals inadequate quality control throughout the supply chain.

Use both peptides in separate experimental groups to isolate mechanisms. Design a three-arm study: follistatin alone, Sermorelin alone, and combination treatment. This approach differentiates myostatin-dependent muscle growth (follistatin's direct effect) from GH/IGF-1-mediated anabolic processes (Sermorelin's systemic effect). A 2020 rodent study using this design found that combined administration produced additive but not synergistic effects. 22% greater lean mass gain than either peptide alone, but the mechanisms remained distinct at the molecular level.

Collect blood samples at 15-minute intervals for 90–120 minutes post-injection to capture the entire pulse profile. GH peaks 30–60 minutes after subcutaneous Sermorelin administration in most models, then returns to baseline by 2–3 hours. Use ELISA or chemiluminescence immunoassay with sensitivity ≤0.05 ng/mL. GH pulses range 5–25 ng/mL depending on dose and subject characteristics. Pre-dose samples establish baseline; samples beyond 120 minutes confirm return to baseline, validating that observed GH elevation was Sermorelin-induced rather than endogenous pulsatile variation.

Check three variables: (1) injection site. Follistatin must be administered intramuscularly or subcutaneously near target tissue for localized effects, (2) baseline myostatin expression. Subjects with already-low myostatin (e.g., certain genetic strains) won't respond to further inhibition, (3) peptide purity and reconstitution. Aggregated or denatured follistatin loses binding affinity. If all three check out, the research model may not be appropriate. Follistatin doesn't directly stimulate muscle protein synthesis; it removes inhibition, so subjects need adequate nutritional substrate and mechanical loading stimulus.

Verify peptide integrity immediately using HPLC or mass spectrometry if available. Degraded Sermorelin shows fragmentation peaks at m/z ratios inconsistent with the intact 3.36 kDa molecular weight. If verification isn't possible, discard the vial and reconstitute fresh peptide. Do not attempt to compensate by increasing dose. Degraded peptide fragments can produce inconsistent or null results. Our team recommends storing reconstituted Sermorelin in single-use aliquots at -20°C (stable up to 3 months frozen) rather than multi-dose vials at 4°C to eliminate this risk.

This is why certificate of analysis (CoA) documentation matters. Reputable suppliers provide third-party HPLC verification showing exact peptide content and purity percentage. A vial labelled '5mg sermorelin' with 96% purity contains 4.8mg active peptide. Your reconstitution calculation must use 4.8mg, not 5mg, to achieve target concentration. Suppliers without CoA documentation introduce unquantifiable dosing error. Research-grade peptides from Real Peptides include batch-specific purity data, allowing concentration calculations accurate to within 1–2%.

Split the dose across multiple injection sites rather than exceeding the 5mg/mL aggregation threshold. A 1.5mg total dose at 5mg/mL requires 0.3mL. Within single-site limits. A 1.5mg dose at 10mg/mL would only require 0.15mL, but the aggregated peptide in that 10mg/mL solution would deliver inconsistent results across administrations as aggregation progresses over the storage period. Multi-site injection at safe concentrations is standard practice in pharmacokinetic studies requiring supra-physiological dosing.

Do not attempt to correct concentration by adding more diluent or more peptide. The introduced volume changes create non-linear dilution errors and increase contamination risk. Prepare a fresh vial at the correct concentration and document the error in your research log. If the incorrectly prepared solution hasn't been used, it can be reserved for non-critical preliminary work where exact concentration is less critical, but it should not be used for data collection in formal study protocols.